Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 4.4% - Here's What Happened

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report)'s stock price fell 4.4% during trading on Tuesday . The company traded as low as $28.05 and last traded at $28.02. 92,307 shares changed hands during trading, a decline of 87% from the average session volume of 699,357 shares. The stock had previously closed at $29.30.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on AGIO shares. Royal Bank of Canada raised their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 10th. Scotiabank lifted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, December 9th. StockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, HC Wainwright started coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of "Hold" and an average price target of $56.57.

Agios Pharmaceuticals Price Performance

The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 2.27 and a beta of 0.83. The firm's fifty day moving average is $32.55 and its 200 day moving average is $40.23.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the business's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company's stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 4.93% of the company's stock.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter worth $39,000. Frazier Life Sciences Management L.P. increased its position in Agios Pharmaceuticals by 2.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company's stock worth $35,152,000 after buying an additional 25,600 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Agios Pharmaceuticals by 8.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,835 shares of the biopharmaceutical company's stock worth $4,036,000 after buying an additional 9,606 shares during the last quarter. Voloridge Investment Management LLC raised its holdings in Agios Pharmaceuticals by 2.1% during the fourth quarter. Voloridge Investment Management LLC now owns 200,481 shares of the biopharmaceutical company's stock valued at $6,588,000 after buying an additional 4,082 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth about $5,337,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.